Press Releases - 2021-06-23

Date	Title	Company
23-Jun-2021	GSK und Vir Biotechnology verkünden weiteren Fortschritt des klinischen Entwicklungsprogramms COMET für Sotrovimab	GSK und Vir Biotechnology
23-Jun-2021	Copley Scientific joins the Industries Forum of the Taskforce for Lung Health	Copley Scientific
23-Jun-2021	DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma	Janssen Pharmaceutical Companies of Johnson & Johnson
23-Jun-2021	Chiesi accelerates path toward full sustainability despite Covid-19 pandemic	Chiesi
23-Jun-2021	Advanced Biological Laboratories Obtained a Derogatory Authorization from the French National Agency for Medicines and Health Products Safety (ANSM) for its UltraGene Assay SARS-CoV-2 452R & 484K & 484Q Mutations	Advanced Biological Laboratories (ABL)
23-Jun-2021	SmiLe alumnus GPX Medical sold its first NEOLA® system	SmiLe Incubator
23-Jun-2021	Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation	eTheRNA immunotherapies NV
23-Jun-2021	Wellcome Photography Prize 2021	Four Communications
23-Jun-2021	Sosei Heptares Initiates Phase 1 Trial with Novel Small-Molecule CGRP Antagonist under Collaboration with Biohaven	Sosei Group Corporation
23-Jun-2021	Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody	Tiziana Life Sciences plc
23-Jun-2021	Santhera Announces Phase 4 LEROS Trial with Raxone® Met Primary Endpoint in Patients with Leber’s Hereditary Optic Neuropathy	Santhera Pharmaceuticals
23-Jun-2021	Demy-Colton Announces BioFuture™ Conference to be held at Cure, Deerfield’s Vertical Innovation Campus in New York City	Demy-Colton
23-Jun-2021	HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations	HUTCHMED
23-Jun-2021	Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis	Genmab
23-Jun-2021	LEO Pharma announces MHRA and EC approval of Adtralza▼ (tralokinumab) as the first and only treatment specifically targeting IL-13 only for adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy	LEO Pharma
23-Jun-2021	European Commission Purchases Additional 150 Million Doses of Moderna’s COVID-19 Vaccine for Delivery in 2022	Moderna, Inc.
23-Jun-2021	ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific	ProBioGen
23-Jun-2021	Immutep to evaluate efti in triple combination therapy phase I study with chemotherapy and an anti-PD-1 therapy	Immutep Limited
23-Jun-2021	Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting	Santhera Pharmaceuticals
23-Jun-2021	Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	Nordic Nanovector ASA